M&A / Deals Parkinson’s charity partners Biognosys on biomarker project PharmaphorumA new R D project will try to develop assays for LRRK2, a biomarker linked to Parkinson's that has emerged as a major drug target in the disease.M&A / DealsNeuroscienceRead full story pharminent April 15, 2026 Pharmaphorum A new R D project will try to develop assays for LRRK2, a biomarker linked to Parkinson’s that has emerged as a major drug target in the disease. M&A / DealsNeuroscienceRead full story Post navigation Previous: Daiichi exits OTC, with $1.55bn unit sale to SuntoryNext: Takeda continues to prune partnerships, cuts ties with mRNA-targeting Veritas In Silico Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026